Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$109.64M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$112.13M
Net Profit Margin
-270.22%
TTM Avg
-342.92%
3Y Avg
-204.73%
5Y Avg
-136.49%
Market Cap
$109.91M
Net Profit Margin
-14.78%
TTM Avg
-35.00%
3Y Avg
-39.46%
5Y Avg
-38.67%
Market Cap
$114.10M
Net Profit Margin
-959.76%
TTM Avg
-1140.14%
3Y Avg
-4837.22%
5Y Avg
-4160.74%
Market Cap
$112.03M
Net Profit Margin
-52.59%
TTM Avg
-29.17%
3Y Avg
-18.36%
5Y Avg
-9.63%
Market Cap
$109.21M
Net Profit Margin
-175.78%
TTM Avg
-311.79%
3Y Avg
-369.50%
5Y Avg
-4193.27%
Market Cap
$115.16M
Net Profit Margin
-114.77%
TTM Avg
-120.72%
3Y Avg
-96.63%
5Y Avg
-81.33%
Market Cap
$107.45M
Net Profit Margin
31.95%
TTM Avg
15.97%
3Y Avg
7.99%
5Y Avg
5.33%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $109.64M | 0.00% | 0.00% | 0.00% | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $112.13M | -270.22% | -342.92% | -204.73% | -136.49% |
| Apyx Medical Corporation (APYX)vs › | $109.91M | -14.78% | -35.00% | -39.46% | -38.67% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.10M | -959.76% | -1140.14% | -4837.22% | -4160.74% |
| BGM Group Ltd. (BGM)vs › | $112.03M | -52.59% | -29.17% | -18.36% | -9.63% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $109.21M | -175.78% | -311.79% | -369.50% | -4193.27% |
| Immunic, Inc. (IMUX)vs › | $108.43M | 0.00% | 0.00% | 0.00% | 0.00% |
| MaxCyte, Inc. (MXCT)vs › | $115.16M | -114.77% | -120.72% | -96.63% | -81.33% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.45M | 31.95% | 15.97% | 7.99% | 5.33% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.83M | -33.92% | -11.74% | -13.15% | -11.88% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
